USRE47770EExpiredUtilityPatentIndex 59
Recombinant production of mixtures of antibodies
Est. expiryJul 18, 2022(expired)· nominal 20-yr term from priority
C07K 16/2803C07K 16/32C07K 16/2833C07K 16/30C07K 16/2851C07K 2317/31C07K 2317/515A61K 2039/507C07K 2317/56C07K 2317/734C07K 2317/73C07K 2319/30C07K 2317/732C07K 2317/622C07K 2317/626C07K 16/00C12P 21/005C07K 2317/21C07K 16/2896C07K 2317/12C07K 2317/51A61K 39/39558C07K 16/10Y02P20/582C07K 2317/50C12N 2795/00041
59
PatentIndex Score
1
Cited by
1,608
References
26
Claims
Abstract
Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A composition comprising a mixture of two or three non-identical antibodies and a suitable pharmaceutically acceptable carrier,
wherein two different heavy chains and a common immunoglobulin light chain able to pair with the two different heavy chains are present in the mixture of the two or three non-identical antibodies, and
wherein the mixture of two or three non-identical antibodies comprises:
a bispecific antibody and at least one monospecific antibody, and
wherein at least one of the two different heavy chains is modified as compared to wild-type.
2. The composition of claim 1 , wherein the mixture comprises a bispecific antibody and two different monospecific antibodies.
3. The composition of claim 1 , wherein the two or three non-identical antibodies have differing specificities for the same target antigen.
4. The composition of claim 1 , wherein the two or three non-identical antibodies have differing affinity for the same target epitope.
5. The composition of claim 1 , wherein the two or three non-identical antibodies bind to different epitopes on the same target antigen.
6. The composition of claim 1 , wherein the two or three non-identical antibodies bind to different antigens.
7. The composition of claim 1 , wherein the two or three non-identical antibodies are independently selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, and IgM.
8. The composition of claim 1 , wherein the different immunoglobulin heavy chains are of IgG isotype.
9. A composition comprising a mixture of two or three non-identical antibodies that have been produced in the same host cells,
wherein two different heavy chains and a common immunoglobulin light chain are present in the mixture of the two or three non-identical antibodies, wherein the two different heavy chains are able to pair to said common light chain, wherein the two different heavy chains have different binding specificities, and wherein said heavy chains further differ in their constant regions sufficiently so that the amount of bispecific antibodies is decreased as compared to the theoretical percentage of bispecific antibodies, and wherein the mixture of two or three non-identical antibodies comprises two different monospecific antibodies.
10. A composition comprising a mixture of two or three non-identical antibodies and a suitable carrier,
wherein only two different heavy chains are present in the two or three antibodies, wherein a common immunoglobulin light chain able to pair with the two different heavy chains is present in the mixture of the two or three non-identical antibodies, and wherein the mixture of two or three non-identical antibodies comprises:
a bispecific antibody and at least one monospecific antibody.
11. A composition comprising a mixture of two or three non-identical antibodies and a suitable carrier,
wherein two different heavy chains are present in the two or three antibodies, wherein only a common immunoglobulin light chain able to pair with the two different heavy chains is present in the mixture of the two or three antibodies, and wherein the mixture of two or three non-identical antibodies comprises:
a bispecific antibody and at least one monospecific antibody.
12. A composition comprising a mixture of two or three non-identical antibodies and a suitable pharmaceutically acceptable carrier,
wherein only two different heavy chains are present in the two or three antibodies, and
wherein a common immunoglobulin light chain able to pair with the two different heavy chains is present in the mixture of the two or three non-identical antibodies, and
wherein the mixture of two or three non-identical antibodies comprises a monospecific antibody and a bispecific antibody, and
wherein at least one of the two different heavy chains is modified as compared to wild-type.
13. A composition comprising a mixture of two or three non-identical antibodies and a suitable pharmaceutically acceptable carrier,
wherein two different heavy chains are present in the two or three antibodies, and
wherein only a common immunoglobulin light chain able to pair with the two different heavy chains is present in the mixture of the two or three antibodies, and
wherein the mixture of two or three non-identical antibodies comprises a monospecific antibody and a bispecific antibody, and
wherein at least one of the two different heavy chains is modified as compared to wild-type.
14. A composition comprising at least a first antibody and a second antibody,
wherein the first and second antibodies have a common light chain,
wherein the first antibody comprises two copies of a first heavy chain,
wherein the second antibody comprises one copy of the first heavy chain and one copy of a second heavy chain, and
wherein the first heavy chain and the second heavy chain are different from one another, and
wherein at least one of the two different heavy chains is modified as compared to wild-type.
15. The composition of claim 1, wherein the mixture comprises three non-identical antibodies.
16. The composition of claim 1, wherein the common light chain is identical in each light chain/heavy chain pair of the two or three non-identical antibodies.
17. The composition of claim 1, wherein the common light chain is the only light chain present in the composition.
18. The composition of claim 1, wherein the two different heavy chains differ in their variable region.
19. The composition of claim 1, wherein the two different heavy chains differ in both the variable region and constant region.
20. The composition of claim 1, wherein the mixture of two or three non-identical antibodies has been produced in the same host cells.
21. The composition of claim 1, wherein:
the mixture comprises three non-identical antibodies; the common light chain is identical in each light chain/heavy chain pair of the two or three non-identical antibodies; the common light chain is the only light chain present in the composition; the three non-identical antibodies have been produced in the same host cells; and the two different heavy chains differ in their variable region.
22. The composition of claim 1, wherein the mixture of two or three non-identical antibodies has been isolated from the host cells which produce the antibodies.
23. The composition of claim 1, wherein the light chain is able to pair with one of the two heavy chains present in the mixture.
24. The composition of claim 1 wherein the two or three non-identical antibodies have a different affinity for the same target epitope.
25. The composition of claim 24 wherein the different affinity is analyzed by surface plasmon resonance.
26. The composition of claim 1, wherein the two or three non-identical antibodies have been isolated separately or as a mixture from a culture of the host cell.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.